| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transplant Co-Morbidity Superpanel v0.9 | CYP4F2 | Bryony Thompson Marked gene: CYP4F2 as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transplant Co-Morbidity Superpanel v0.9 | CYP4F2 | Bryony Thompson Gene: cyp4f2 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transplant Co-Morbidity Superpanel v0.9 | CYP4F2 | Bryony Thompson Classified gene: CYP4F2 as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transplant Co-Morbidity Superpanel v0.9 | CYP4F2 | Bryony Thompson Gene: cyp4f2 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transplant Co-Morbidity Superpanel v0.4 | CYP4F2 |
Claire Fryer-Smith gene: CYP4F2 was added gene: CYP4F2 was added to Transplant Co-Morbidity Superpanel. Sources: Expert list Mode of inheritance for gene: CYP4F2 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: CYP4F2 were set to 25370453; 20555338; 19207028; 18250228 Phenotypes for gene: CYP4F2 were set to Warfarin dosage sensitivity MIM# 122700 Review for gene: CYP4F2 was set to GREEN Added comment: It is involved in guidelines for warfarin https://www.pharmgkb.org/gene/PA27121/overview Sources: Expert list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||